NCT01458054View on ClinicalTrials.gov

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 27, 2011

Primary Completion Date

November 28, 2011

Study Completion Date

November 28, 2011

Conditions
Hepatitis C
Interventions
DRUG

Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)

GSK2336805 and Omeprazole

DRUG

Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)

GSK2336805 and Ritonavir

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults | Biotech Hunter | Biotech Hunter